Diclofenac vs. Placebo in a Randomized Double Blind Controlled Trial in Post ERCP Pancreatitis
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
1. The most common complication of endoscopic retrograde cholangio-pancreaticography (ERCP)
is pancreatitis.
2. Several studies showed that non-steroidal anti-inflammatory drugs (NSAIDs) can prevent
the post ERCP pancreatitis, the investigators used diclofenac vs placebo.
3. The effect of diclofenac in prevention of that complication, was measured by the number
of patients who developed pancreatitis, and compare it with the placebo.
4. The investigators collected 199 patients, 17 excluded, 182 completed the study, all of
them underwent the intervention called "ERCP", and randomized to have either Diclofenac
or Placebo before the procedure.